Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-8400 in Relapsed or Refractory Waldenstrom's Macroglobulinemia
NCT02092909Phase 2Terminated
- Sponsor
- Aceragen, Inc.
- Start
- Mar 2014
- Primary completion
- Apr 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of bazlitoran in Waldenström macroglobulinemia (WM), sponsored by Aceragen, Inc.. Started Mar 2014; status: terminated.
02
Drugs
bazlitoran
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02092909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092909.